相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recen Inhibi Updates on he Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Heena Singla et al.
CURRENT CANCER DRUG TARGETS (2018)
Health Risk Assessment of Occupationally Pesticide-Exposed Population of Cancer Prone Area of Punjab
Gurpreet Kaur et al.
TOXICOLOGICAL SCIENCES (2018)
Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding
Peng Liao et al.
MOLECULAR CELL (2017)
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Heena Singla et al.
CURRENT CANCER DRUG TARGETS (2017)
Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors
Daniela Furrer et al.
BREAST (2016)
Gene-environment interaction and risk of breast cancer
Anja Rudolph et al.
BRITISH JOURNAL OF CANCER (2016)
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Anthony Ferrari et al.
NATURE COMMUNICATIONS (2016)
Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer
X. Han et al.
ANNALS OF ONCOLOGY (2014)
Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
M. Tanioka et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Reproductive risk factors and breast cancer subtypes: a review of the literature
Kristin N. Anderson et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web
A. Dittrich et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2014)
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
M. Cizkova et al.
BRITISH JOURNAL OF CANCER (2013)
HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer
Naglaa R. AbdRaboh et al.
DISEASE MARKERS (2013)
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
John B. McIntyre et al.
GYNECOLOGIC ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
Ariella B. Hanker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pesticide residues in human breast milk: Risk assessment for infants from Punjab, India
J. S. Bedi et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2013)
p53 codon 72 polymorphism and breast cancer risk: A meta-analysis
Jing Hou et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2013)
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2012)
HER-2/neu Gene Codon 655 (Ile/Val) Polymorphism in Breast Carcinoma Patients
Ezgi Sezgin et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2011)
Cyclin D1 G870A Polymorphism and Breast Cancer Risk: A Meta-Analysis Involving 23,998 Subjects
June Yang et al.
ONCOLOGY RESEARCH (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis
Cheng Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Advances in systemic therapy for HER2-positive metastatic breast cancer
Phuong Khanh H. Morrow et al.
BREAST CANCER RESEARCH (2009)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Role of the HER2 [lle655Val] genetic polymorphism in tumorogenesis and in the risk of-trastuzumab-related cardiotoxicity
S. Beauclair et al.
ANNALS OF ONCOLOGY (2007)
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
K Oda et al.
CANCER RESEARCH (2005)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
HER2 polymorphism and breast cancer risk in Portugal
D Pinto et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2004)
A putative molecular-activation switch in the transmembrane domain of erbB2
SJ Fleishman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
DW Xie et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
